Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ImmunoGen, Inc.
Alliance to develop novel anticancer compound
November 6th, 2004
ImmunoGen, Inc., (IMGN) and Biogen Idec, Inc., (BIIB) announced that Biogen Idec has licensed exclusive rights to use ImmunoGen's proprietary Tumor-Activated Prodrug (TAP) technology with antibodies to an undisclosed tumor cell target. Under the terms of the agreement, Biogen Idec will receive exclusive worldwide rights to develop and commercialize anticancer therapeutics that comprise an antibody developed by Biogen Idec to an undisclosed tumor cell target and a maytansinoid cell-killing agent developed by ImmunoGen. ImmunoGen has developed its maytansinoid cell-killing agents specifically for antibody-directed delivery to cancer cells. ...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2004-11-06)
|
